comprehensive -WSS

comprehensive

author：fashion 2025-09-06 04:36:07 - browse：16

Gilead office remdesivir — Yichuan Cao/Sipa USA

Gilead Sciences said Monday it will acquire CymaBay Therapeutics for $4.3 billion, adding a new treatment for a liver disease that is on track for approval later this year.

The deal values CymaBay at $32.50 per share, 27% higher than the stock’s close last Friday. That’s a relatively small takeout premium, but CymaBay shares have doubled in value since last fall on growing investor confidence in the company’s lead drug and speculation that the company could be acquired.

CymaBay’s drug, called seladelpar, is being developed for the treatment of primary biliary cholangitis, or PBC, a type of liver disease mainly affecting women that causes decreased liver function, and debilitating itching and fatigue. Progression of PBC to more advanced stages increases the risk of liver-related death.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Diversity in medical illustrations gets boost from Chidiebere Ibe

entertainment

knowledge

WSS

Some top drug companies are starting to take action on climate

What AAP's gender

What we owe ALS patients — and why one company fell short

Lawsuit highlights wrinkle for disputes over surprise medical bills

Complete sequence of Y chromosome published for first time

Will an HIV vaccine ever be a reality?

explore

comprehensive

Wikipedia

Jerome Adams on the need for new antivirals for Covid

Some top drug companies are starting to take action on climate

Peter Hotez and the public health issue of online harassment

NYU Langone launches private ChatGPT for its health care data

What does generative AI mean for health care? We asked experts

How Long Island became the ‘eugenics capital of the world’

Supreme Court strikes down use of affirmative action

Experts study whether long Covid risk adds up with each reinfection

Peter Hotez and the public health issue of online harassment

Apellis safety probe of eye disease drug centers on injection needle

Wikipedia

AstraZeneca bets AAV gene therapy will still deliver the goods

Diversity in medical illustrations gets boost from Chidiebere Ibe

How a symptom of dementia informs our understanding of creativity

Some top drug companies are starting to take action on climate

Setback for rare diseases as Taysha Gene Therapies pulls back

Medicare explains how it will choose drugs for negotiation

knowledge

entertainment

knowledge

entertainment